Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
NCT ID: NCT05335707
Last Updated: 2024-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2022-09-14
2023-08-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer
NCT02716896
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
NCT06427824
Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer
NCT02699853
Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer
NCT04273724
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
NCT02252393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and females age ≥ 65 years
* Diagnosis/disease status
* Histologically proven muscle-invasive bladder cancer (MIBC) without metastatic disease.
* Patients planning to undergo neoadjuvant chemotherapy and radical cystectomy for MIBC.
* Treatment with investigational systemic therapy is permitted if participants will be receiving chemotherapy as part of their treatment plan
Exclusion Criteria
* Any other known invasive malignancy within previous 2 years with the following EXCEPT: low grade prostate cancer on active surveillance, chronic lymphocytic leukemia CLL on surveillance / observation, non-melanoma skin cancers
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Kansas Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elizabeth Wulff-Burchfield, MD
Assistant Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIT-2021-GerioncBladder
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.